ProCE Banner Activity

Predictors of Response to Immune Checkpoint Inhibitors: PD-L1

Slideset Download
In this downloadable slideset, David R. Spigel, MD, reviews key data and best practice for the use of PD-L1 biomarker testing in patients who may be eligible for immune checkpoint inhibitors.

Released: March 29, 2019

Expiration: March 27, 2020

Share

Faculty

David R. Spigel

David R. Spigel, MD

Chief Scientific Officer
Director,
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Foundation Medicine

Faculty Disclosure

Primary Author

David R. Spigel, MD

Chief Scientific Officer
Director,
Lung Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee